wjb001 + paclitaxel-albumin

WJB001 + paclitaxel-albumin is a combination therapy consisting of **WJB001** and **paclitaxel-albumin (nab-paclitaxel)**. Nab-paclitaxel consists of paclitaxel nanoparticles bound to albumin, enhancing drug delivery to tumor tissues and reducing toxicity associated with solvent-based paclitaxel. It is used to inhibit cancer cell growth by stabilizing microtubules, thereby disrupting cell division. The mechanism of WJB001 is not strongly characterized in available sources, but nab-paclitaxel is extensively studied as a cytotoxic antineoplastic agent, particularly for breast, pancreatic, lung, and gastric cancers. The combination is investigational and may increase efficacy or alter tolerability compared to single agents, though concurrent administration can present stability concerns.

Brand names

abraxane

Other names

nab-paclitaxelalbumin-bound paclitaxelABI-007ABI007ABI 007